

Table 5
Frequency of polymorphisms in HIV-1 RT from treatment-naïve subtypes B and CRF01_AE.

HXB2	Residue	Subtype B (n = 42)	Subtype CRF01_AE (n = 76)	Region	
E	6	E36,D6	D74,E2	DNA polymerase	
K	11	K42	T55,K18,S3		
V	35	V33,I6,M1,R1,T1	T75,M1		
T	39	T41,A1	K75,E1		
K	43	K40,N1,R1	E73,K2,A1		
K	122	K31,E9,R1	E74,K2		
D	123	D28,E13,	S68,N6,D2		
Q	174	Q42	K72,N2,Q2		
D	177	D32,E9,N1	E73,D3		
I	178	I40,I1,M1	M47,I28,V1		
R	211	R19,K15,G7,S1	S70,K5,N1		
K	238	K41,R1	R56,K20		
V	245	V19,E11,M5,K3,T2,A1,I1	E74,Q1,V1		
T	286	T25,A14,V2,P1	A61,T15		
E	291	E40,D2	D70,E6		
V	292	V41,I1	I70,V6		
E	312	E41	T73,N3		
I	326	I38,V4	V63,I13		Connection domain
I	329	I34,L6,V2	V73,I3		
G	335	G41,N1	D75,G1		
M	357	M33,T5,V3,I1	K75,R1		
G	359	G39,S3	S76		
K	366	K38,R4	R73,K3		
A	371	A34,V7,T1	V76		
K	390	K24,R18	R65,K11		
T	403	T23,M13,I4,A1	M63,T13		
N	447	N39,S3	S72,N4		
N	460	N22,D19,S1	D67,N9		
D	471	D41,N1	E76		
Q	480	Q40,H2	H75,Y1		
L	491	L23,S12,P3,V3,A1	S69,P5,L2		
Q	512	K35,Q3,R2,T1,N1	R72,K4		
N	519	S31,N11	N69,S7		
A	534	A41,T1	S76		
V	536	T42	V76		
A	554	A28,T8,S4,N2	S76		

Amino acid substitutions in treatment-naïve B and CRF01_AE cases differ significantly ($p < 0.05$).

Second, our comparison of resistance patterns in naïve and exposed groups led to several interesting observations about differences in drug-resistance acquisition pathways. Among these differences, the d4T-resistance patterns were especially intriguing. The naïve group showed three patterns of d4T-resistance mutations. The first pathway was acquisition of the Q151M multi-resistant mutation. Q151M is an alternative pathway of AZT resistance that does not depend on ATP binding and excision (Lennerstrand et al., 2001a, 2001b) and is known as the major

AZT resistance pathway in HIV-2 (Boyer et al., 2006; Perach et al., 1997). The second pathway was acquisition of D67N, known as part of d4T resistance-related mutations. The third pathway could be the K65R acquisition route. Although few cases (2%) were found in our study population, K65R has been reported to be predominantly selected by GPOvir administration (Sungkanuparph et al., 2007, 2008) (6% and 7%). The mechanisms of the selection process for these three pathways, how they are selected, and how they evolved remain unclear. Other than these three types of resis-

Table 6
Mutations/polymorphisms outside known drug-resistance mutations.

HXB HXB2	Residue	Mutation frequency		p	Region
		Naïve group (n = 76)	Failure group (n = 49)		
E	312	T(73), N(3)	T(44), N(5)	–	RT/DNA polymerase
Y	318	Y(76)	Y(47), F(2)	–	Connection domain
G	333	G(76)	G(49)	–	
G	335	D(75), G(1)	D(48), G(1)	–	<0.001
N	348	N(76)	N(41), I(8)	–	
A	360	A(76)	A(48), V(1)	–	
V	365	V(76)	V(48), I(1)	–	
A	371	V(76)	V(49)	–	
A	376	A(71), S(4), T(1)	A(43), S(4), T(2)	–	
E	399	E(75), D(1)	E(33), D(16)	<0.001	RNase H domain
N	447	S(72), N(4)	S(37), N(12)	–	
Q	509	Q(76)	Q(48), L(1)	–	
P	537	P(76)	P(44), S(5)	<0.05	
I	542	I(75), M(1)	I(40), M(9)	<0.001	

Subtype B consensus amino acid sequence is shown as a reference on the left side of each position. Bold represents new substitutions not previously reported.

tance mutation-acquisition pathways, it is possible that resistance mutations had been transmitted.

In contrast to multiple pathways for acquiring d4T resistance in the naïve group, d4T resistance acquisition in the exposed group was much simpler. d4T resistance-related mutations were the most frequently observed mutations, and few K65R or Q151M mutations were detected. As many cases had a history of AZT as mono- or dual therapy, d4T resistance-related mutations appear to have been induced during previous AZT exposure, and these mutations were re-selected by GPOvir treatment. We also observed different mutation patterns in NNRTI resistance. K103N was less prevalent in the exposed group. Some of the differences observed between our two study groups may be attributed to intra- or intermolecular interference, which has been reported to affect drug-resistant mutation-acquisition pathways (Parikh et al., 2006; Quan et al., 1998).

Regarding mutations in the connection and RNase H domains, these two domains are not usually analyzed in clinical samples since most RT inhibitor-resistance mutations map to the DNA polymerase domain of RT (Clavel and Hance, 2004). Thus, less information is available for these domains in CRF01_AE. Therefore, we collected information on these two domains from our cohort. We found that G335C/D and A371V, which have been reported to confer AZT resistance in subtype B (Brehm et al., 2007; Nikolenko et al., 2007), were natural polymorphisms of CRF01_AE, and N348I, E399D, P537S, and I542M appeared to be induced by GPOvir exposure. Among these last 4 mutations, N348I and E399D were reported to affect AZT and NNRTI resistance in subtype B (Hachiya et al., 2008; Poveda et al., 2008); P537S and I542M are two newly discovered mutations in our study.

In conclusion, our study shows the potential of GPOvir for antiretroviral treatment-naïve and -exposed groups and demonstrates differences in drug-resistance acquisition pathways. Selection of pre-existing mutations and different pathways was affected by interference with drug-resistance mutations. Although developing countries currently have no alternative treatment regimen to GPOvir, its usage could be detrimental to salvage regimens because (1) d4T selects the multi-drug-resistance mutations, Q151M and K65R, the latter conferring resistance to tenofovir, and (2) both 3TC and nevirapine have low genetic barriers to acquiring drug resistance. More studies are needed to provide a better basis for selecting second-line treatments after GPOvir failure.

Acknowledgments

We are grateful to all the participants of the Lampang cohort. We appreciate the technical assistance of Mrs. Arunratsamee Katesomboon, Mr. Amornsak Kladnil, Ms. Suthira Kasemsuk, Ms. Sriprai Seneewong-na yuthaya, Ms. Nutira Boonna, and Mr. Prapan Wongnamnong. We are indebted to Dr. Shiino Teichiro, Dr. Shiro Ibe and Dr. Junko Shibata for guiding the analysis of genetic diversity of the RT gene. We also thank Ms. Claire Baldwin for her assistance in preparing the manuscript. This study was supported by The Ministry of Public Health Thailand, Ministry of Health, Labor and Welfare of Japan, and Human Sciences Grant.

References

- Arts, E.J., Quiñones-Mateu, M.E., Albright, J.L., Marois, J.P., Hough, C., Gu, Z., Wainberg, M.A., 1998. 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. *J. Virol.* 72, 4858–4865.
- Boyer, P.L., Sarafianos, S.G., Clark, P.K., Arnold, E., Hughes, S.H., 2006. Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? *PLoS Pathog.* 2, e10.
- Brehm, J.H., Koontz, D., Meteer, J.D., Pathak, V., Sluis-Cremer, N., Mellors, J.W., 2007. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. *J. Virol.* 81, 7852–7859.
- Brenner, B., Turner, D., Oliveira, M., Moisi, D., Deterio, M., Carobene, M., Marlink, R.G., Schapiro, J., Roger, M., Wainberg, M.A., 2003. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. *AIDS* 17, F1–5.
- Chetchotisakd, P., Anunnatsiri, S., Kiertiburanakul, S., Sutthent, R., Anekthananon, T., Bowonwatanuwong, C., Kowadisaburana, B., Supparatpinyo, K., Horsakulthai, M., Chasombat, S., Ruxrungtham, K., 2006. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. *J. Int. Assoc. Physicians AIDS Care (Chic Ill)* 5, 152–156.
- Clavel, F., Hance, A.J., 2004. HIV drug resistance. *N. Engl. J. Med.* 350, 1023–1035.
- Delviks-Frankenberry, K.A., Nikolenko, G.N., Barr, R., Pathak, V.K., 2007. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. *J. Virol.* 81, 6837–6845.
- Deshpande, A., Jauvin, V., Magnin, N., Pinson, P., Faure, M., Masquelier, B., Aurillac-Lavignolle, V., Fleury, H.J., 2007. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. *AIDS Res. Hum. Retroviruses* 23, 335–340.
- Ehteshami, M., Beilhartz, G.L., Scarth, B.J., Tchesnokov, E.P., McCormick, S., Wynhoven, B., Harrigan, P.R., Götte, M., 2008. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. *J. Biol. Chem.* 283, 22222–22232.
- Gonzales, M.J., Wu, T.D., Taylor, J., Belitskaya, I., Kantor, R., Israelski, D., Chou, S., Zolopa, A.R., Fessel, W.J., Shafer, R.W., 2003. Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. *AIDS* 17, 791–799.
- Grossman, Z., Istomin, V., Averbuch, D., Lorber, M., Risenberg, K., Levi, I., Chowers, M., Burke, M., Bar Yaacov, N., Schapiro, J.M., 2004. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. *AIDS* 18, 909–915.
- Hachiya, A., Kodama, E.N., Sarafianos, S.G., Schuckmann, M.M., Sakagami, Y., Matsuoka, M., Takiguchi, M., Gatanaga, H., Oka, S., 2008. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. *J. Virol.* 82, 3261–3270.
- Hirsch, M.S., Brun-Vézinet, F., Clotet, B., Conway, B., Kuritzkes, D.R., D'Aquila, R.T., Demeter, L.M., Hammer, S.M., Johnson, V.A., Loveday, C., Mellors, J.W., Jacobsen, D.M., Richman, D.D., 2003. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. *Clin. Infect. Dis.* 37, 113–128.
- Johnson, V.A., Brun-Vézinet, F., Clotet, B., Gunthard, H.F., Kuritzkes, D.R., Pillay, D., Schapiro, J.M., Richman, D.D., 2008. Update of the Drug Resistance Mutations in HIV-1. *Top. HIV Med.* 16, 138–145.
- Julias, J.G., McWilliams, M.J., Sarafianos, S.G., Alvord, W.G., Arnold, E., Hughes, S.H., 2003. Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. *J. Virol.* 77, 8548–8554.
- Kantor, R., Katzenstein, D., 2003. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. *AIDS Rev.* 5, 25–35.
- Kimura, M., 1981. Estimation of evolutionary distances between homologous nucleotide sequences. *Proc. Natl. Acad. Sci. U.S.A.* 78, 454–458.
- Kumarasamy, N., Solomon, S., Chaguturu, S.K., Mahajan, A.P., Flanagan, T.P., Balakrishnan, P., Mayer, K.H., 2003. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. *AIDS* 17, 2267–2269.
- Lacey, S.F., Larder, B.A., 1994. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-dideoxy-2',3'-dideoxythymidine in cell culture. *Antimicrob. Agents Chemother.* 38, 1428–1432.
- Lennerstrand, J., Hertogs, K., Stammers, D.K., Larder, B.A., 2001a. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. *J. Virol.* 75, 7202–7205.
- Lennerstrand, J., Stammers, D.K., Larder, B.A., 2001b. Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. *Antimicrob. Agents Chemother.* 45, 2144–2146.
- Liu, L., Lu, H.Z., Henry, M., Tamalet, C., 2007. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China. *J. Med. Virol.* 79, 1593–1599.
- Loemba, H., Brenner, B., Parniak, M.A., Ma'ayan, S., Spira, B., Moisi, D., Oliveira, M., Deterio, M., Wainberg, M.A., 2002. Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. *Antimicrob. Agents Chemother.* 46, 2087–2094.
- Ministry of Public Health, 2008. The Asian Epidemic Model (AEM) Projections for HIV/AIDS in Thailand: 2005–2025.
- Myint, L., Ariyoshi, K., Yan, H., Frater, A.J., Auwanit, W., Pathipvanith, P., Yamada, K., Matsuda, M., Chiba, T., Fujita, K., McClure, M., Weber, J.N., Sugiura, W., 2002. Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (Subtype E) human immunodeficiency virus type 1. *Antimicrob. Agents Chemother.* 46, 3861–3868.

- Nikolenko, G.N., Delviks-Frankenberry, K.A., Palmer, S., Maldarelli, F., Fivash Jr., M.J., Coffin, J.M., Pathak, V.K., 2007. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance. *Proc. Natl. Acad. Sci. U.S.A.* 104, 317–322.
- Ntemgwaa, M., Wainberg, M.A., Oliveira, M., Moisi, D., Lalonde, R., Micheli, V., Brenner, B.G., 2007. Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. *Antimicrob. Agents Chemother.* 51, 3861–3869.
- Parikh, U.M., Bachelier, L., Koontz, D., Mellors, J.W., 2006. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. *J. Virol.* 80, 4971–4977.
- Perach, M., Rubinek, T., Hughes, S.H., Hizi, A., 1997. Analysis of HIV-2 RT mutants provides evidence that resistance of HIV-1 RT and HIV-2 RT to nucleoside analogs involves a repositioning of the template-primer. *J. Mol. Biol.* 268, 648–654.
- Poveda, E., de Mendoza, C., Pattery, T., González Mdel, M., Villacian, J., Soriano, V., 2008. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. *AIDS* 22, 2395–2398.
- Pujari, S.N., Patel, A.K., Naik, E., Patel, K.K., Dravid, A., Patel, J.K., Mane, A.A., Bhagat, S., 2004. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India. *J. Acquir. Immune Defic. Syndr.* 37, 1566–1569.
- Quan, Y., Gu, Z., Li, X., Liang, C., Parniak, M.A., Wainberg, M.A., 1998. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates. *J. Mol. Biol.* 277, 237–247.
- Saeng-Aroon, S., Yoshida, L.M., Ariyoshi, K., Taguchi, M., Pathipvanich, P., Rojanawiwat, A., Matsuda, M., Kannagi, M., Sawanpanyalert, P., Sugiura, W., Auwanit, W., 2007. An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V. *AIDS Res. Hum. Retroviruses* 23, 1461–1468.
- Santos, A.F., Lengruher, R.B., Soares, E.A., Jere, A., Sprinz, E., Martinez, A.M., Silveira, J., Sion, F.S., Pathak, V.K., Soares, M.A., 2008. Conservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patients. *PLoS One* 3, e1781.
- Sungkanuparph, S., Manosuthi, W., Kiertiburanakul, S., Piyavong, B., Chumpathat, N., Chantratita, W., 2007. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. *Clin. Infect. Dis.* 44, 447–452.
- Sungkanuparph, S., Manosuthi, W., Kiertiburanakul, S., Saekang, N., Pairoj, W., Chantratita, W., 2008. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine. *J. Clin. Virol.* 41, 310–313.
- Tamura, K., Dudley, J., Nei, M., Kumar, S., 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. *Mol. Biol. Evol.* 24, 1596–1599.
- Tsuchiya, N., Pathipvanich, P., Yasuda, T., Mukoyama, Y., Rojanawiwat, A., Matsubayashi, T., Saeng-aroon, S., Auwanit, W., Matsuyama, A., Sawanpanyalert, P., Ariyoshi, K., 2009. Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand. *Southeast Asian J. Trop. Med. Public Health* 40, 71–82.
- Waters, J.M., O'Neal, W., White, K.L., Wakeford, C., Lansdon, E.B., Harris, J., Svarovskaia, E.S., Miller, M.D., Borroto-Esoda, K., 2009. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. *Antivir. Ther.* 14, 231–239.
- WHO, 2003. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach.
- Yap, S.H., Sheen, C.W., Fahey, J., Zanin, M., Tyssen, D., Lima, V.D., Wynhoven, B., Kuiper, M., Sluis-Cremer, N., Harrigan, P.R., Tachedjian, G., 2007. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. *PLoS Med.* 4, e335.
- Zelina, S., Sheen, C.W., Radzio, J., Mellors, J.W., Sluis-Cremer, N., 2008. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine. *Antimicrob. Agents Chemother.* 52, 157–163.
- Zhou, J., Paton, N.I., Ditangco, R., Chen, Y.M., Kamarulzaman, A., Kumarasamy, N., Lee, C.K., Li, P.C., Merati, T.P., Phanuphak, P., Pujari, S., Vibhagool, A., Zhang, F., Chuah, J., Frost, K.R., Cooper, D.A., Law, M.G., 2007. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. *HIV Med.* 8, 8–16.

Structural and Energetic Analysis on the Complexes of Clinically Isolated Subtype C HIV-1 Proteases and Approved Inhibitors by Molecular Dynamics Simulation

Shou Matsuyama,[†] Ay Aydan,[†] Hiroataka Ode,[†] Masayuki Hata,[‡] Wataru Sugiura,^{§,||} and Tyuji Hoshino^{*†}

Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba 263-8522, Japan, College of Pharmaceutical Sciences, Matsuyama University, 4-2 Bunkyo-cho, Matsuyama 790-8578, Japan, AIDS Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-1011, Japan, and Clinical Research Center, Nagoya Medical Center, 4-1-1 Sannomaru, naka-ku, Nagoya 460-0001, Japan

Received: August 28, 2009; Revised Manuscript Received: October 14, 2009

HIV-1 has a large genetic diversity. Subtype B HIV-1 is commonly found in patients in developed countries. In contrast, an increasing number of patients are infected with the non-B subtype viruses, especially with subtype C HIV-1, in developing countries. It remains to be clarified how mutations or polymorphisms in non-B subtype HIV-1 influence the efficacy of the approved inhibitors. In this study, we have performed molecular dynamics simulations on clinically isolated subtype C HIV-1 proteases in complex with three kinds of approved inhibitors. From the structural and energetic viewpoints, we identified the polymorphisms influencing on the binding of the inhibitors. The effect of the V82I mutation on the association with chemicals and the reason for rare appearance of the D30N mutation in subtype C HIV-1 were discussed in terms of the change of geometry of the residues in HIV-1 protease.

Introduction

Total number of patients infected with human immunodeficiency virus (HIV) is supposed to be 3.3 million in the world in 2007 and HIV infectious disease is still one of the serious threats to human beings.¹ HIV is separated into two types, HIV-1 and HIV-2, and most of the patients in the world carry HIV-1. According to its high genetic diversity, HIV-1 is classified into three groups, M (Main), O (Outlier), and N (non-M/non-O). Viruses in group M are further divided into nine subtypes and several circulating recombinant forms (CRFs). Among nine subtypes, subtype B HIV-1 is major in developed countries in North America and Europe. In contrast, the viruses other than subtype B, so-called non-B subtype HIV-1, are mainly found among patients in developing countries in Africa and South East Asia. Over half of the patients are infected with subtype C HIV-1 in the world.

HIV-1 has a gene coding the viral enzyme called HIV-1 protease (HIV-1 PR).² Since the inhibition of the action of this enzyme leads no maturation of viral precursor and incomplete replication of the virus,³ the inhibitors against HIV-1 PR have been prescribed in the chemotherapy for HIV-1 infectious disease.^{4–12} All the PR inhibitors released so far were mainly developed against subtype B HIV-1 PR. HIV-1 PR has a formation of homodimer and each monomer consists of 99 amino residues (Figure 1A). Polymorphisms are frequently observed in HIV-1 PRs.¹³ For example, the K20I mutation dominantly appears in the PRs of subtype G and CRF02_AG, M36I appears in PRs of subtypes A, C, D, F, G, CRF01_AE, and CRF02_AG, V82I appears in subtype G, and I93L appears

in subtype C. These polymorphisms are closely related to the difference in mutational pathways leading to emergence of the drug resistant variants among subtypes. As some epidemiological studies suggested, the polymorphisms in PRs will change drug efficacy among different subtypes.^{14–24} It is interesting to note that some mutations such as D30N, which is known for the primary mutation for drug resistance in subtype B PR, are rarely seen in non-B subtype PRs.^{18,25,26} A study based on the clinical data with hundreds of the subtype C- and subtype B-infected patients clearly suggested that a difference was observed in frequency of the D30N mutation between subtypes C and B, while little difference was seen for the L90 M mutation.²⁵ Further, significant differences were found in the rates of appearance of M36I, L63P, A71 V, V77I, and I93L between subtypes C and B. Hence, the difference in polymorphism between subtypes should be seriously considered for planning the chemotherapeutic protocol for the nonsubtype B-infected patients. Accordingly, the accumulation of the knowledge on the susceptibility of inhibitors or the emergence rate of drug resistant mutations is required for non-B subtype HIV-1.

In this study, we have performed molecular dynamics (MD) simulation on the complexes of clinically isolated subtype C HIV-1 PRs and its inhibitors. Three kinds of HIV-1 PRs are examined; two of them were isolated from patients who have no experience on the treatment with PR inhibitors, and one was isolated from a patient who failed in the therapy with one of the PR inhibitors; nelfinavir (NFV), because of the appearance of drug resistant mutations (Figure 1B, and Figure S1 and Table S1 in Supporting Information). Three kinds of inhibitors: atazanavir (ATV), nelfinavir (NFV) and saquinavir (SQV), have been examined through the present computational study (Figure 1C).

Additional MD simulations have been performed on the complexes of the subtype B HIV-1 PR and the inhibitors

* To whom correspondence should be addressed. Tel: +81-43-290-2926. Fax: +81-43-290-2925. E-mail: hoshino@faculty.chiba-u.jp.

[†] Chiba University.

[‡] Matsuyama University.

[§] National Institute of Infectious Diseases.

^{||} Nagoya Medical Center.




Figure 1. (A) Structure of HIV-1 PR. Locations of two catalytic aspartates are shown in the ball and stick representation. (B) Clinically isolated subtype C HIV-1 PR: PR(#1), PR(#2), and PR(#3). The red spheres indicate the D30N, M46L, and N88D mutations that are the primary mutations causing resistance to NFV. The orange sphere represents L10F, the secondary mutation to NFV. The green spheres represent the natural polymorphism seen in subtype C HIV-1 PR, differentiated from subtype B HIV-1 PR. The coloring of the spheres is based on HIVdb in Stanford University.²³ (C) Chemical structures of ATV, NFV, SQV.

introducing a single amino mutation. The aim of these calculations is to examine the difference in binding affinity or binding structure with the inhibitors between subtype B and subtype C HIV-1 PRs, and to clarify the change in mechanism for conferring drug resistance from the structural viewpoint. We particularly focus on (i) the role of the V82I mutation that is a common polymorphism seen in non-B subtype HIV-1 PR, and (ii) the effect of the D30N mutation in subtype C HIV-1 PR. Since subtype C HIV-1 PR has not sufficiently been surveyed in terms of the susceptibility for approved inhibitors and the emergence probability of drug resistant mutations, the information obtained in this study will give a hint to select the proper inhibitors for patients infected with subtype C HIV-1 and be helpful for the therapy for HIV-1 infectious disease in developing countries.

Methods

Molecular Dynamics (MD) Simulations. Minimizations and MD simulations were carried out using the Sander module of AMBER8.²⁷ The AMBER ff03 force field²⁸ was used as the parameters for proteins, ions, and water molecules. The general AMBER force field²⁹ was used as the parameters for ATV, NFV, and SQV. Our originally developed torsion parameters for the benzamide moiety in NFV, CA-CA-C-N and CA-CA-C

-O, were applied.³⁰ Atom charges of inhibitors were determined from the electrostatic potential obtained from quantum chemical calculations, followed by the restrained electrostatic potential (RESP) fitting.³¹ The stable structure of each inhibitor was determined through the geometry optimization at the HF/6-31G(d,p) level and, subsequently, the electrostatic potential was calculated at the B3LYP/cc-pVTZ level under the ether-phase condition. The quantum chemical calculations were executed with Gaussian03 program.³²

We performed simulations of three clinically isolated subtype C HIV-1 PRs in complex with ATV, NFV, and SQV. These HIV-1 PRs were labeled as PR(#1), PR(#2), and PR(#3). Further, we labeled each complexes as PR(#1)-ATV, PR(#1)-NFV, PR(#1)-SQV, PR(#2)-ATV, PR(#2)-NFV, PR(#2)-SQV, PR(#3)-ATV, PR(#3)-NFV, and PR(#3)-SQV. Simulations of subtype B HIV-1 PR in complex with ATV, NFV, and SQV were also performed. This HIV-1 PR was labeled as PR(WT), and the complexes were as PR(WT)-ATV, PR(WT)-NFV, and PR(WT)-SQV. The sequence for HXB2³³ was applied to PR(WT). Simulation of PR(WT) containing the V82I mutation in complex with ATV was further performed. This HIV-1 PR was labeled as PR(V82I) and the complex of PR(V82I) and ATV was as PR(V82I)-ATV. Each initial structure for HIV-1

PR in complex with ATV, NFV and SQV was constructed from the atom coordinates of an X-ray crystal structure (Protein Data Bank (PDB) code, 2AQU, 1OHR, 1HXB)^{21,34,35} and the respective mutations were introduced using the LEaP module of AMBER8. First, we downloaded the file of HIV-1 PR containing each inhibitor from PDB site. Second, the PDB file was edited to change the residue names of the mutated residues and to delete the description on the side-chain atoms of the mutated residues. Third, the coordinates of the side-chain atoms of the mutated residues were automatically generated by LEaP module. Fourth, each model was placed in a rectangular box filled with about 8000 TIP3P water molecules³⁶ with all of the crystal water molecules remaining. The cutoff distance for the long-range electrostatic and van der Waals energy terms was set to 12.0 Å. The expansion and shrinkage of all covalent bonds connecting to hydrogen atom were constrained using the SHAKE algorithm.³⁷ Periodic boundary conditions were applied to avoid the edge effect in all calculations.

Energy minimization was achieved in three steps. Initially, movement was allowed only for water molecules and ions. Next, inhibitor and mutated residues were allowed to move in addition to the water molecules and ions. In this step, the favorable configurations of the side chains of the mutated residues were obtained because steric collisions of them were minimized. Finally, all atoms were allowed to move freely. In each step, energy minimization was executed by the steepest descent method for the first 10 000 cycles and the conjugated gradient method for the subsequent 10 000 cycles. After a 0.1 ns heating calculation until 310 K using the NVT ensemble condition, a 3.0 ns equilibrating calculation was executed at 1.0 atm and at 310 K under the NPT ensemble condition with an integration time step of 2.0 fs. The calculation steps described above were performed both for two protonation states of catalytic residues, protonated D25/unprotonated D25' and unprotonated D25/protonated D25'. Since the MD simulations showed no large fluctuations after about 2.5 ns equilibrating calculations for most of the complexes (Supporting Information Figures S2, S3), we evaluated the energies of the respective protonation states for each complex and selected the favorable one for the subsequent extended simulation. Additional 4.0 ns simulations were performed for the selected protonation state for each complex model. After 5.0 ns of the totally 7.0 ns equilibrating calculation, the MD simulations of all complexes showed little fluctuations (Supporting Information Figures S3, S4).

As for the complexes of PR(V82I)-ATV, the protonation state was determined in the same manner, using the simulation data for 3.0 ns. The 7.0 ns MD simulation was performed for the protonation state of unprotonated D25/protonated D25'. Additionally other 7.0 ns MD simulations were executed for protease only models, that is, PR(#1), PR(#2), and PR(#3) without inhibitors for the sake of comparison in structure.

Protonation State of Catalytic Residues. Protonation states of the catalytic aspartic acids D25 and D25' of HIV-1 PR vary depending on the binding of inhibitor or the type of HIV-1 PR.³⁸ Thus, appropriate protonation states of the catalytic aspartic acids should be determined for each model. We considered two kinds of protonation states.^{39–41} One is a combination of protonated D25/unprotonated D25' states, and the other is the opposite combination. To determine the protonation states when each inhibitor is bound to each HIV-1 PR, the free energies of two kinds of protonation states were compared using calculation data obtained for the last 0.5 ns of 3.0 ns MD simulations. The free energies were calculated by the MM/PBSA method,^{42,43} only for the inhibitor-PR complex without subtracting the values for

inhibitor only and/or unbound PR. The same parameter set as used in the equilibrating calculations was adopted for computing electrostatic and van der Waals energy terms, and no cutoff was applied for the calculation. Since the dielectric constants for the interior of proteins is considered to be in the range of 2 to 4, the interior dielectric constant was set to 2.0.⁴¹ The outside dielectric constant was set to 80.0. The pbsa module of AMBER8 was used to solve the Poisson-Boltzmann (PB) equation. PR(WT)-ATV, PR(WT)-SQV, PR(#1)-ATV, PR(#1)-NFV, PR(#1)-SQV, PR(#2)-ATV, PR(#2)-NFV, PR(#2)-SQV, PR(#3)-ATV, and PR(#3)-SQV have been found to favor the combination of protonated D25 and unprotonated D25'. The other complexes, PR(WT)-NFV and PR(#3)-NFV, prefer the combination of unprotonated D25 and protonated D25' (Supporting Information Table S2).

Binding Free-Energy Calculation. The binding free energy⁴⁴ was calculated by the following equation

$$\Delta G_b = \Delta E_{\text{int}}^{\text{ele}} + \Delta E_{\text{int}}^{\text{vdw}} + \Delta G_{\text{sol}} - T\Delta S_v$$

where ΔG_b is the binding free energy in solution, $\Delta E_{\text{int}}^{\text{ele}}$ and $\Delta E_{\text{int}}^{\text{vdw}}$ are electrostatic and van der Waals interaction energies between an inhibitor and a protein, ΔG_{sol} is the solvation energy, and $T\Delta S_v$ is the contribution of vibrational entropy. The parameters for cutoff and dielectric constant were the same as those used in determining the protonation state. The snapshot structures were obtained every 10 ps from the trajectories of the last 1.0 ns simulation to calculate the terms $\Delta E_{\text{int}}^{\text{ele}}$, $\Delta E_{\text{int}}^{\text{vdw}}$, and ΔG_{sol} . The vibrational entropic term $T\Delta S_v$ was calculated using nmode module of AMBER9 at 310 K. The snapshot structures were collected every 50 ps from the last 1.0 ns trajectories to estimate $T\Delta S_v$. The modified GB model developed by Onufriev, Bashford, and Case⁴⁵ was used to calculate the solvation energy term. The MM/GBSA results were highly correlated with the MM/PBSA results, as we described previously.³⁰ To examine the energetic contribution of each residue, the energy without vibrational entropy was decomposed into the contribution from each individual residue by the MM/GBSA method.

Hydrogen Bond Criteria. The formation of a hydrogen bond was defined in terms of distance and orientation. The combination of donor D, hydrogen H, and acceptor A atoms with a D–H···A configuration was regarded as a hydrogen bond when the distance between donor D and acceptor A was shorter than 3.5 Å and the angle H–D–A was smaller than 60.0°.

Results

Sequence of HIV-1 PRs. We investigated three clinically isolated HIV-1s. Two of them, #1 and #2, were isolated from patients who had no experience in the treatment with any PR inhibitors. The other, #3, was isolated from a patient who failed in treatment with NFV. In this study, we labeled PRs of these clinically isolated HIV-1s as PR(#1), PR(#2), and PR(#3). The PR of subtype B HXB2 strain³³ was labeled as PR(WT).

The amino acid sequence of each PR was compared with that of PR(WT). PR(#1) has 14 amino acid mutations, T12S, K14R, I15V, L19I, K20R, M36I, N37D, R40K, R57K, L63P, H69K, V82I, L89M, and I93L, and PR(#2) has 13 amino acid mutations, T12P, I15V, K20R, M36I, N37K, R40N, R57K, Q61E, L63T, H69K, T74S, L89M, and I93L (Figure 1B). All these mutated residues are located at the nonactive site of PR, except for V82I of PR(#1). According to HIVdb of Stanford University,²³ both kinds of PRs have no primary mutations that

TABLE 1: Prediction of Susceptibility of the Inhibitors against the Clinically Isolated PRs^a

	ATV	NFV	SQV
PR(#1)	susceptible	susceptible	susceptible
PR(#2)	slightly resistant	susceptible	susceptible
PR(#3)	slightly resistant	resistant	susceptible

^a An inhibitor is judged to be susceptible, slightly resistant, or resistant when the binding free energy to a PR is lower than 2 kcal/mol, higher by 2–5 kcal/mol, or higher more than 5 kcal/mol compared with that of the wild-type PR, respectively.

are highly involved in the resistance against PR inhibitors. In contrast, PR(#3) has D30N, M46L, and N88D mutations that are primary mutations for drug resistance and also one secondary mutation L10F (Figure 1B). PR(#3) further contains nine amino acid mutations, T12S, I13V, I15V, L19I, E35D, M36V, R40K, H69K, and L89I. It has also already been reported that some mutations such as K20R, M36I/V, and H69K are related to resistance against PR inhibitors and these mutations are seen in polymorphisms.^{22,23}

Computational Prediction of the Susceptibility of Inhibitors. The susceptibility of three kinds of inhibitors for the respective isolated HIV-1 PRs are judged from our simulation and summarized in Table 1. This judgment is based on the difference in binding free energy between the complexes with the isolated and wild-type PRs, which is presented as $\Delta\Delta G_b$ in Table 2. In PR(#1), no energetic disadvantage is observed for NFV and SQV, and the energetic disadvantage is negligible for ATV compared to PR(WT). Therefore, all PR inhibitors are concluded to be susceptible to this variant. In PR(#2), an energetic disadvantage is observed only for the complex with ATV. Hence this mutant is judged to be weakly resistant only to ATV. PR(#3) shows the energetic disadvantage for ATV and NFV and is concluded to be resistant to these two inhibitors.

To support the judgment on the above prediction for susceptibility, the statistical analysis was carried out on the data for the binding energy calculation.⁴⁶ All the computed sampling data for the binding free energy were confirmed to be in the normal distribution. The *f* test with a significance level of 0.05 was performed to examine whether the data have the different variance or not between WT and each mutant for the respective inhibitors. Since the hypothesis was rejected for ATV and SQV for all the mutants, the computed sampling data for ATV and SQV were concluded to have the same variance between WT and each mutant. Therefore, Student's *t* test was applied for ATV and SQV, while Welch's *t* test was for NFV. According to the Student's *t* test with a significance level of 0.01, the means of the binding free energies for PR(#2)-ATV and PR(#3)-ATV were different from that for PR(WT)-ATV. For PR(#1)-ATV, the null hypothesis was not rejected even with a significance level of 0.05. The Welch's *t* test with a significance level of 0.01 indicated that the means of the binding free energies for PR(#1)-NFV and PR(#3)-NFV were different from that of PR(WT)-NFV. The Student's *t* test with a significance level of 0.01 suggested the difference of the means of the binding free energies for PR(#1)-SQV and PR(#2)-SQV compared to that for PR(WT)-SQV.

Binding Free Energy. Table 2 shows the detailed energy values in the computation of the binding free energy for the complexes of the respective PRs and three kinds of inhibitors. PR(#1) contains no primary mutations known for resistance to subtype B virus. The energy gain in $\Delta\Delta G_b$ is observed for NFV and SQV compared to PR(WT), and the calculation shows a slight energy loss for ATV. PR(#2) also contains no primary

mutations and the energy gain in $\Delta\Delta G_b$ is seen only for NFV and SQV. Namely PR(#1) and PR(#2) show similar change in binding energy. Since PR(#3) was isolated from the patient who failed in the NFV treatment, it is straightforwardly understood that a large energy loss in $\Delta\Delta G_b$ is observed for the complex with NFV. PR(#3) also shows the energy loss for ATV, compared to that for PR(WT). For the purpose of examining the effect of single mutation, another MD simulation was performed for the PR in which an amino mutation of V82I was introduced in PR(WT). The complex of PR(V82I) and ATV showed no disadvantage in binding free energy compared to PR(WT).

Table 2 indicates that the electrostatic term mainly dominates the binding affinity of the complex while the vibrational entropic term has some degree of influence. As for the complexes showing the increase in binding affinity, the entropic term considerably contributes to the stability of the complex in PR(#1)-SQV and PR(#2)-SQV while van der Waals interaction enhances the stability of the complexes of PR(#1)-ATV and PR(#2)-NFV. The balance of the contributions of electrostatic, van der Waals, and entropic terms also varies for the complexes showing the decrease in binding affinity. PR(#2)-ATV exhibits energetic disadvantage in van der Waals term while PR(#3)-NFV and PR(#3)-SQV show the disadvantage in the electrostatic term. The standard deviation in binding free energy calculation is considerably large. Particularly the standard deviation of entropic term is large compared to $\Delta\Delta G_b$. Accordingly, we must be careful for the interpretation of the calculated binding free energy.

Hydrogen Bonding Networks. All direct and one-water-molecule-mediated hydrogen bonds between HIV-1 PR and inhibitor were examined for every complex (Supporting Information Tables S3–S6). To survey the formation of hydrogen bonds, we sampled 1000 snapshot structures from the trajectory of the last 1.0 ns MD simulation. In all cases, the hydroxyl group existing at the center of the inhibitors makes a direct hydrogen bond to D25 or D25' of PR. I50 or I50' residue of PRs keeps an one-water-molecule-mediated hydrogen bond to the inhibitor. Furthermore, different hydrogen bond networks are observed among PR(#1), PR(#2), PR(#3), and PR(WT) in complex with each inhibitor.

Direct hydrogen bonds from ATV are connected to D29' and G48' in PR(WT)-ATV. PR(#1) hardly has the direct hydrogen bond to ATV. PR(#2) keeps the hydrogen bond to G48' and D29', while the hydrogen bond to D29' is weakened. PR(#3) loses both hydrogen bonds seen in PR(WT), whereas a new hydrogen bond to D29 appears. As for NFV, PR(WT) has a direct hydrogen bond between the side chain of D30 and NFV. This hydrogen bond is kept in PR(#1)-NFV and PR(#2)-NFV. Although D30 was substituted for N30 in PR(#3), the side chain of N30 still keeps hydrogen bond to NFV. As for SQV, G48 in PR(WT) forms a direct hydrogen bond to SQV. In PR(#1)-SQV, G48 and D30 make direct hydrogen bonds to SQV. G48 in PR(#2) keeps a hydrogen bond to SQV as well as PR(WT). In contrast, the hydrogen bond from N2 of SQV disappears in PR(#3).

Change in Conformation of PRs and Inhibitors. The averaged structures of PR and inhibitor in each model were compared with those for the complex in PR(WT). The averaged structure was obtained from 1000 snapshot structures during the last 1.0 ns MD simulation. To compare the structure with that of PR(WT), the averaged structure of each mutant was superimposed on PR(WT) in respect of atom coordinates of N, C α , and C atoms and, then, the root-mean-square deviation

TABLE 2: Binding Free Energy of the Complex of HIV-1 PR and Its Inhibitor

	$\Delta G_{\text{int}}^{\text{ele}}$ (kcal/mol)	$\Delta G_{\text{int}}^{\text{dw}}$ (kcal/mol)	ΔG_{sol} (kcal/mol)	$-T\Delta S$ (kcal/mol)	ΔG_b (kcal/mol)	$\Delta\Delta G_b$ (kcal/mol) ^a
PR(WT)-ATV	-15.7 ± 1.7	-74.1 ± 3.5	11.6 ± 1.5	26.2 ± 7.5	-52.0	
PR(WT)-NFV	-24.2 ± 2.1	-66.9 ± 4.2	12.5 ± 1.7	29.1 ± 6.8	-49.5	
PR(WT)-SQV	-15.1 ± 2.9	-70.1 ± 4.3	10.0 ± 1.3	31.1 ± 6.0	-44.1	
PR(#1)-ATV	-12.8 ± 2.2	-79.9 ± 3.0	12.9 ± 1.1	28.8 ± 8.6	-51.0	+1.0
PR(#1)-NFV	-18.4 ± 3.0	-72.2 ± 3.4	11.9 ± 1.5	25.0 ± 9.0	-53.7	-4.2
PR(#1)-SQV	-21.7 ± 4.2	-72.4 ± 3.9	13.6 ± 1.7	27.0 ± 9.6	-53.5	-9.4
PR(#2)-ATV	-17.7 ± 3.6	-70.5 ± 4.1	12.8 ± 1.9	27.0 ± 5.8	-48.4	+3.6
PR(#2)-NFV	-20.0 ± 5.9	-69.1 ± 2.8	13.0 ± 1.2	26.2 ± 7.4	-49.9	-0.4
PR(#2)-SQV	-16.6 ± 3.5	-67.9 ± 4.7	10.6 ± 1.8	25.6 ± 8.6	-48.3	-4.2
PR(#3)-ATV	-12.2 ± 2.1	-76.5 ± 3.6	12.0 ± 1.2	28.2 ± 7.4	-48.5	+3.5
PR(#3)-NFV	-13.1 ± 1.9	-65.5 ± 3.2	10.5 ± 1.2	25.3 ± 6.6	-42.8	+6.7
PR(#3)-SQV	-13.0 ± 2.5	-71.5 ± 3.9	9.0 ± 0.9	30.6 ± 6.2	-44.9	-0.8
PR(V82I)-ATV	-24.4 ± 2.4	-80.8 ± 4.7	15.4 ± 1.5	23.6 ± 6.9	-66.2	-13.2

^a Difference from PR(WT).

TABLE 3: Genotype Assay of Clinically Isolated PRs in Complex with Each Inhibitor

	ATV	NFV	SQV
PR(#1)	susceptible ^a	susceptible	susceptible
PR(#2)	susceptible	susceptible	susceptible
PR(#3)	intermediate resistance ^b	high-level resistance ^c	low-level resistance ^d

^a Virus of this category hardly shows the reduction in susceptibility to the drug. ^b Virus of this category shows certain degree of drug resistance between the low-level and the high-level resistances. ^c Virus of this category shows the highest levels of the in vitro drug resistance and/or the patients infected with viruses of this category generally have little or no virologic response to treatment with the drug. ^d Virus of this category reduces the in vitro susceptibility to the drug and/or the patients with viruses of this category may have a suboptimal virologic response to treatment.

(rmsd) value was calculated (Figure 2A). Since the residues located at the outer part of PR largely fluctuate (Supporting Information Figure S6), we focused only on the structural change of the residues located near the active site of HIV-1 PRs. A prominent structural change is seen in the complexes of PR(#1)-ATV, PR(#1)-NFV, PR(#2)-NFV, and PR(#3)-NFV at the 80s loop which corresponds to 80–84th residues of PR. PR(#1)-ATV and PR(#3)-ATV show a structural change at the flap region. No significant changes are observed for the other complexes around the binding pocket. In contrast, the change in binding pose is more clearly observed for the inhibitors. In the complexes of PR(#1), the ring parts of the respective inhibitors, 3'-phenylpyridine group in ATV and phenylsulfanyl group in NFV, show large deviations, compared with that of PR(WT). These large structural deviations are also seen in the complexes of PR(#2). PR(#3) shows the deviation not only at the ring part but also for the whole part of all the inhibitors. The quinoline group in SQV shows a considerable deviation in PR(#3), while PR(#1) and PR(#2) has little change compared with PR(WT).

Discussion

PR(#1) and PR(#2). Both PR(#1) and PR(#2) were derived from the patients who were naive for the treatment with PR inhibitors. The polymorphisms at the 20th, 36th, 69th, and 93rd residues are commonly seen in both sequences of PR(#1) and PR(#2). All these amino acid mutations were reported to be involved in drug resistance of subtype B HIV-1 PR.^{14–22} It is important to note that these mutations are not the primary mutation for drug resistance but the secondary mutation accompanying with some primary mutations. Hence, judging

from the knowledge accumulated on subtype B PR, these mutations would not cause the drug resistance by themselves. Indeed, according to HIVdb, the genotype assay web service of Stanford University,²³ both of PR(#1) and PR(#2) were judged not to cause the resistance against the approved PR inhibitors (Table 3). Genotype assay is the prediction method for drug resistance based only on the sequence of the virus and sometimes used in the clinical scene. The calculated binding free energy of the present MD simulation has suggested an almost similar conclusion that NFV and SQV are almost effective for PR(#1) and PR(#2) as well as PR(WT). Only the assessment for PR(#2)-ATV complex is different (Table 1).

V82I Mutation. Our simulation suggests that PR(#2) is weakly resistant only for ATV (Table 1). It is informative to clarify the cause for the difference in efficacy of ATV between PR(#1) and PR(#2). A comparison in the amino sequence between PR(#1) and PR(#2) shows that V82I and V63P mutations appear only in PR(#1). Since the 82nd residue is located at the inhibitor-binding site of PR and has direct interaction with the PR inhibitors, V82I may have some degree of influence on the binding affinity between PR and its inhibitor. The 82nd residue is, further, known as a key residue relating to the recognition of substrate.^{22,47–49} Accordingly, it will be important to examine the effect of the V82I mutation on the PR-ATV complex. Several previous studies with X-ray crystal analysis suggested that the 82nd residue is located at the vicinity of ring part of ATV (3'-phenylpyridil group).^{21,34,35} Our present MD simulation indicates that the V82I mutation causes structural change not only in PR but also in ATV (Figure 2), which leads the stable binding pose of ATV different from that in PR(WT). In PR(WT), the side chain of V82 is positioned with facing to the inner side of the binding pocket (Figure 3A). In contrast, the side chain of I82 faces opposite to the binding pocket (Figure 3B). Furthermore, 3'-phenylpyridyl group of ATV occupies the different space compared to PR(WT). 3'-phenylpyridyl group interacts with the flap region around the 50th residues in PR(WT), while this group is shifted toward I84 in PR(#1). This shift will increase the van der Waals interaction between PR and ATV (Table 2) and, further, induces the formation of hydrogen bond between D25 and ATV (Supporting Information, Tables S3 and S4). The binding free energy for the ATV-PR complex was decomposed into the contributions from the respective residues (Supporting Information, Figure S8). A comparison of the decomposed binding energies of PR(#1), PR(#2), PR(#3) with PR(WT) indicated that noticeable energy loss appears around the residues of A28', D29', G48', and T80'. Inversely, energy gain is observed at the residue of R8 and D29. All these amino residues are located at the active site, and the




Figure 2. (A) Three-dimensional plot of rmsd of the average structure of each PR measured from PR(WT). PRs are shown in the colored tube representation. (B) Three-dimensional plot of rmsd of the average structure of each PR inhibitor measured from PR(WT). Inhibitors are shown in the colored stick representation. The color means the magnitude of rmsd shown in the bottom bar. The superimposed gray tubes in A and sticks in B represent the structure in PR(WT).

energy changes were mainly caused by the displacement of the binding position of ATV.

In order to examine whether the above structural changes are indeed caused by the V82I mutation, we executed another 3.0 ns MD simulation on PR(V82I)-ATV complex, where PR(V82I) model was constructed by introducing the V82I mutation into PR(WT). This simulation on PR(V82I) shows that the side chain of V82I faces opposite to the binding pocket and 3'-phenylpyridyl group of ATV is shifted toward I84 (Figure 3C). Our energy calculation shows no loss in binding free energy both in PR(#1) and PR(V82I) (Table 2). That is, the V82I mutation causes the structural change, but no decrease in binding

affinity. In contrast to PR(#1), PR(#2) does not contain the V82I mutation and PR(#2)-ATV complex shows the loss in binding free energy compared to PR(WT). In the binding structure of the PR(#2)-ATV complex, 3'-phenylpyridyl group of ATV is slightly shifted as well as PR(#1), but the 82nd residue is not completely shifted from the original position (Figure 3D). Because of the slight positional shift, 3'-phenylpyridyl group still keep the interaction with the flap region of PR in a similar manner with PR(WT). This halfway position of ATV is energetically unfavorable. Therefore, we can conclude that the V82I mutation causes the alteration of the position of side chain of I82 and the shift of ring part of ATV toward 80' loop. This




Figure 3. Structure of ATV and the 82nd residue in each model. ATV and the residue are shown by sticks and PR is by tubes. (A) PR(WT)-ATV, (B) PR(#1)-ATV, (C) PR(#2)-ATV, (D) PR(V82I)-ATV.

shift keeps the energetic stability of the complex of PR and ATV. The presence of the V82I mutation exerts a strong influence on the binding with ATV and one of the prominent characteristics for subtype C HIV-1 PR.

PR(#3). Since PR(#3) was derived from the patient who failed in the treatment with NFV, PR(#3) contains mutations known to confer resistance against NFV. The genotype assay based on the HIVdb of Stanford University suggested the resistance to NFV and, further, indicated the resistance to ATV and SQV. The calculated binding free energy in our present work gave a similar conclusion. That is, a large loss in binding free energy is observed for the PR(#3)-NFV complex, compared with PR(WT), and the energy loss is also seen for the complexes with ATV. The D30N mutation appearing in PR(#3) is well-known as the primary mutation causing the resistance against NFV and frequently seen in the patient who was infected with subtype B HIV-1 and failed in the treatment with NFV.^{22,50} In subtype B HIV-1 PR, the break of the hydrogen bond between the side chain of N30 and NFV due to the D30N mutation is the main reason for causing resistance to NFV.^{30,51,52} The hydrogen bond between the side chain of N30 and NFV is, however, maintained in PR(#3) in contrast with the subtype B D30N-mutated PR (Supporting Information, Tables S3 and S6). As our previous simulation on the D30N/M36 V doubly mutated subtype B PR suggested, the M36 V mutation in PR(#3), which is also reported to be involved in resistance to NFV,¹³ will induce the formation of hydrogen bonds between NFV and N30.⁵² Therefore, the M36 V mutation is effective for keeping the hydrogen bond both in subtype B and subtype C PRs. The hydrogen bond was observed to disappear for a while for 7.0 MD simulation and the *m*-phenyl group of NFV was occasionally change its position in the PR(#3)-NFV complex. This means that the chain of N30 cannot make a strong hydrogen bond with *m*-phenyl group of NFV compared to D30. This will be a reason for low binding affinity of NFV to PR(#3).

In the PR(#3)-ATV complex, the binding free energy was diminished compared to PR(WT) due to the shift of the binding

position of ATV. This position shift is reflected in the disappearance of hydrogen bonds seen in PR(WT) and the appearance of another direct hydrogen bond between D29 and O2 of ATV (Supporting Information, Table S6). No energy loss was observed in the PR(#3)-SQV complex. This result is compatible with the findings that PR(#3) contains few mutations related to SQV resistance.²²

D30N Mutation. PR(#3) is the subtype C HIV-1 PR containing the D30N mutation. The appearance of the D30N mutation was, however, reported to be rare in the subtype C HIV-1 showing the drug resistance to NFV.^{13,18,25,26} Therefore, it is informative to clarify the reason why the D30N mutation rarely appears in subtype C HIV-1 PR from the structural viewpoint. Some experimental findings indicated that the rare appearance of the D30N mutation in subtype C HIV-1 PR is closely related to the replication ability of the virus.^{25,26} The replication ability of subtype C HIV-1 containing the D30N/N88D mutation was lower than the variant containing the L90 M mutation, though the D30N/N88D and L90 M mutations are known as the primary mutation conferring resistance against NFV in subtype B HIV-1.²⁶ It has been reported that the 29th and 87th residues in PR are related to the stability of dimer formation.^{53,54} Considering this finding, we paid our attention to the structure of the 29th and 87th residues in the PR(#3)-NFV complex. If the structural stability of HIV-1 PR is reduced, the enzymatic activity of PR to cleave the peptide linkage of substrate will be seriously lowered. The low enzymatic activity will lead to the decrease in replication ability. It was found that the side chain of D29 was shifted toward the inner side of the binding pocket in PR(#3)-NFV, compared to PR(WT)-NFV (Figure 4A,B). Further, the side chain of R87 was displaced opposite to the binding pocket. Our previous simulations suggested that the mutation at the 36th residue influences the geometry of D29.⁵¹ Hence, in order to further examine the influence of the M36 V mutation on the 29th and 87th residues, we have performed another MD simulation on the complex of NFV and PR(WT) containing the D30N/M36 V mutation. This




Figure 4. Structure of NFV and the 29th and 87th residues. ATV and the residues are shown by sticks and PR is by tubes. (A) PR(WT)-NFV, (B) PR(#3)-NFV, (C) PR(D30N/M36 V)-NFV.

simulation showed a structural change at the side chains of the 29th and 87th residues as well as PR(#3) (Figure 4C). Accordingly, we conclude that the D30N/M36 V mutation causes the position shift of the side chains of the 29th and 87th residues in the subtype C HIV-1 PR, which induces the structural instability of HIV-1 PR and leads to the lowering of the enzymatic activity of PR. This low enzymatic activity results in the decrease of the replication ability of HIV-1. Since the replication rate of subtype C virus containing the D30N mutation is low, most of the subtype C HIV-1s resistant to NFV rarely contain the D30N mutation.

Overall Picture of the Structure of Subtype C HIV-1 Protease. On the basis of the results of the present MD simulation, we have proposed the influence of polymorphisms of subtype C HIV-1 PR on the susceptibility of drugs. The discussion was mainly developed from the viewpoint of complex structure of PR and inhibitor. A comparison of structures of PRs with and without the inhibitors clearly shows the difference at the flap region (Supporting Information, Figure S7). The flap tips were displaced upward due to the association with the inhibitor in every complex. This displacement is particularly evident in PR(#1) and PR(#2). PR(#3) markedly shows the

displacement at the flap elbow and fulcrum loop (Supporting Information, Figure S6).

The X-ray crystal analysis is one of the most powerful techniques to investigate the structure of protein. Recently a crystallization of the subtype C PR was achieved by Coman et al.^{54,55} Their first report provided the information on the X-ray crystal structure of the subtype C PR complexed with two kinds of inhibitors, indinavir (IDV) and NFV.⁵⁵ Their second report gave a comparison between the inhibitor-unbound subtype C and B PRs.⁵⁶ The unbound subtype C PR exhibited a larger distance between the two flap tips, a downward displacement of the 36–41's loop, and an increased thermal stability of the 10s loop, compared with subtype B. The increase of the distance of the flap tips is seen in the PR(#1)-ATV and PR(#3)-NFV complexes in our present simulation and the downward displacement of the 36–41's loop is obvious in the PR(#1)-ATV, PR(#2)-NFV, PR(#3)-ATV and PR(#3)-SQV complexes (Figure 2). The increase of stability of the 10s loop is observed in PR(#1)-SQV, PR(#3)-NFV, and PR(#3)-SQV (Supporting Information, Figure S6). Therefore, some of the structural characteristics are compatible with between the X-ray crystal structure and our simulation results. Our calculation will also suggest the drug efficacy of the respective inhibitors on the clinically isolated subtype C PRs. Since structural findings give an insight into the drug resistance, viral fitness, and the response to therapy, it will be required to accumulate much information about the complex structures of the nonsubtype B HIV-1 PRs and inhibitors both from experimental and theoretical approaches. The accumulated data will be useful for the proper choice of inhibitors, which enhances the performance of anti-HIV therapy for the patients infected with the nonsubtype B virus.

Conclusion

MD simulations on the complexes of subtype C HIV-1 PR and three kinds of approved inhibitors were carried out to investigate the influence of natural polymorphisms of subtype C on the change in binding affinity with the inhibitors. The simulation suggested that ATV occasionally decreases the susceptibility to the subtype C HIV-1 PRs. The presence of the V82I polymorphism affects the structural stability of the complex, which is related to the decrease of the susceptibility of ATV. The subtype C HIV-1 PR containing the D30N mutation will confer drug resistance even for the variant containing the M36 V mutation. This is a difference from the subtype B HIV-1 PR. Our MD simulation provided the reason why the emergence rate of the D30N mutation is low for subtype C HIV-1 PR. The low emergence rate is interpreted as a result from the decrease of HIV-1 replication ability of the D30N containing variant.

Acknowledgment. This work was supported by Grant-in-Aid for Scientific Research (C) from Japan Society for the Promotion of Science (JSPS) and by a Health and Labor Science Research Grant for Research on Publicly Essential Drugs and Medical Devices from the Ministry of Health and Labor of Japan. One of the authors (H.O.) gratefully acknowledges the postdoctoral research fellowship from JSPS. A part of this work was also supported by a grant from the Futaba Electronics Memorial Foundation.

Supporting Information Available: Description on the amino sequence of the isolated samples, a list of hydrogen bond networks, the determination of protonation states of catalytic

aspartic acids, B-factors of the respective residues in simulation, comparison of structures with and without the inhibitors, rmsd plots during MD simulations, and the results of principal component analyses were provided. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- (1) Joint United Nations Programme on HIV/AIDS (UNAIDS). 2007 AIDS Epidemic Update UNAIDS. 2007.
- (2) Kräusslich, H. G.; Wimmer, E. *Annu. Rev. Biochem.* **1988**, *57*, 701.
- (3) Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A.; Scolinick, E. M.; Sigal, I. S. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 4686.
- (4) Craig, J. C.; Duncan, I. B.; Hockley, D.; Grief, C.; Roberts, N. A.; Mills, J. S. *Antiviral Res.* **1991**, *16*, 295.
- (5) Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Leven, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, L.-W.; Vastag, K.; Ostvic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. *Proc. Natl. Acad. Sci. U.S.A.* **1994**, *91*, G4096.
- (6) Kempf, D. J.; Marsh, K. C.; Denissen, J. F.; McDonald, E.; Vasavanonda, S.; Flentga, C. A.; Green, B. E.; Fino, L.; Park, C. H.; Kong, X.; Wideburg, N. E.; Saldívar, A.; Ruiz, L.; Kati, W. M.; Sham, H. L.; Robins, T.; Stewart, K. D.; Hsu, A.; Plattner, J. J.; Leonard, J. M.; Norbeck, D. W. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92*, 2484.
- (7) Livingston, D. J.; Pazhanisamy, S.; Porter, D. J.; Partaledis, J. A.; Tung, R. D.; Painter, G. R. *J. Infect. Dis.* **1995**, *172*, 1238.
- (8) Patick, A. K.; Mo, H.; Markowitz, M.; Appelt, K.; Wu, B.; Musick, L.; Kalish, V.; Kaldor, S.; Reich, S.; Ho, D.; Webber, S. *Antimicrob. Agents Chemother.* **1996**, *40*, 292 Erratum, 40, 1575.
- (9) Carrillo, A.; Stewart, K. D.; Sham, H. L.; Norbeck, D. W.; Kohlbrenner, W. E.; Leonard, J. M.; Kempf, D. J.; Molla, A. J. *J. Virol.* **1998**, *72*, 7532.
- (10) Robinson, B. S.; Riccardi, K. A.; Gong, Y. F.; Guo, Q.; Stock, D. A.; Blair, W. S.; Terry, B. J.; Demmie, C. A.; Djang, F.; Colonna, R. J.; Lin, P. F. *Antimicrob. Agents Chemother.* **2000**, *44*, 2093.
- (11) Larder, B. A.; Hertogs, K.; Bloor, S.; van den Eynde, C.; DeCian, W.; Wang, Y.; Freimuth, W. W.; Tarpley, G. *AIDS* **2000**, *14*, 1943.
- (12) Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y. F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. *Antimicrob. Agents Chemother.* **2003**, *47*, 3123.
- (13) Kantor, R.; Katzenstein, D. A.; Efron, B.; Carvalho, A. P.; Wynhoven, B.; Cane, P.; Clarke, J.; Sirivichayakul, S.; Soares, M. A.; Snoeck, J.; Pillay, C.; Rudich, H.; Rodrigues, R.; Holguin, A.; Ariyoshi, K.; Bouzas, M. B.; Cahn, P.; Sugiura, W.; Soriano, V.; Brigido, L. F.; Grossman, Z.; Morris, L.; Vandamme, A. M.; Tanuri, A.; Phanuphak, P.; Weber, J. N.; Pillay, D.; Harrigan, P. R.; Camacho, R.; Schapiro, J. M.; Shafer, R. W. *PLoS Med.* **2005**, *2*, 325.
- (14) Cornelissen, M.; van den Burg, R.; Zörgdrager, F.; Lukashov, V.; Goudsmit, J. *J. Virol.* **1997**, *71*, 6348.
- (15) Pieniazek, D.; Rayfield, M.; Hu, D. J.; Nkengasong, J.; Wiktor, S. Z.; Downing, R.; Biryahwaho, B.; Mastro, T.; Tanuri, A.; Soriano, V.; Lal, R.; Dondero, T. *AIDS* **2000**, *14*, 1489.
- (16) Vergne, L.; Peeters, M.; Mpoudi-Ngole, E.; Bourgeois, A.; Liegeois, F.; Toure-Kane, C.; Mboup, S.; Mulanga-Kabeya, C.; Saman, E.; Jourdan, J.; Reynes, J.; Delaporte, E. *J. Clin. Microbiol.* **2000**, *38*, 3919.
- (17) (a) Grossman, Z.; Vardinon, N.; Chemtob, D.; Alkan, M. L.; Bentwich, Z.; Burke, M.; Gottesman, G.; Istomin, V.; Levi, I.; Maayan, S.; Shahar, E.; Schapiro, J. M. *AIDS* **2001**, *15*, 1453. (b) Grossman, Z.; Vardinon, N.; Chemtob, D.; Alkan, M. L.; Bentwich, Z.; Burke, M.; Gottesman, G.; Istomin, V.; Levi, I.; Maayan, S.; Shahar, E.; Schapiro, J. M. *AIDS* **2001**, *15*, 2209.
- (18) Cane, P. A.; de Ruiter, A.; Rice, P.; Wiselka, M.; Fox, R.; Pillay, D. *J. Clin. Microbiol.* **2001**, *39*, 2652.
- (19) Zhong, P.; Kang, L.; Pan, Q.; Koings, F.; Burda, S.; Ma, L.; Xue, Y.; Zheng, X.; Jin, Z.; Nyambi, P. *JAIDS, J. Acquired Immune Defic. Syndr.* **2003**, *34*, 91.
- (20) Ariyoshi, K.; Matsuda, M.; Miura, H.; Tateishi, S.; Yamada, K.; Sugiura, W. *AIDS, J. Acquired Immune Defic. Syndr.* **2003**, *33*, 336.
- (21) Clemente, J. C.; Coman, R. M.; Thiaville, M. M.; Janka, L. K.; Jeung, J. A.; Nukoolkarn, S.; Govindasamy, L.; Agbandje-McKenna, M.; McKenna, R.; Leelanam, W.; Goodenow, M. M.; Dunn, B. M. *Biochemistry* **2006**, *45*, 5468.
- (22) Johnson, V. A.; Brun-Vézinet, F.; Clotet, N.; Günthard, H. F.; Kuritzkes, D. R.; Pillay, D.; Schapiro, J. M.; Richman, D. D. *Top. HIV Med.* **2008**, *16*, 62.
- (23) Rhee, S.-Y.; Gonzales, M. J.; Kantor, R.; Betts, B. J.; Ravela, J.; Shafer, R. W. *Nucleic Acids Res.* **2003**, *31*, 298.
- (24) Velazquez-Campoy, A.; Todd, M. T.; Vega, S.; Freire, E. *Proc. Natl. Acad. Sci. U.S.A.* **2001**, *98*, 6062.
- (25) Grossman, Z.; Paxinos, E. E.; Averbuch, D.; Maayan, S.; Parkin, N. T.; Dan, E.; Margalit, L.; Valery, I.; Shaked, Y.; Mendelson, E.; Ram, D.; Petropoulos, C. J.; Schapiro, J. M. *Antimicrob. Agents Chemother.* **2004**, *48*, 2159.
- (26) Gonzalez, L. M. F.; Brindeiro, R. M.; Aguiar, R. S.; Pereira, H. S.; Abreu, C. M.; Soares, M. A.; Tanuri, A. *Antimicrob. Agents Chemother.* **2004**, *48*, 3552.
- (27) Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Wang, B.; Pearlman, D. A.; Crowley, M.; Brozell, S.; Tsui, V.; Gohlke, H.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Schafmeister, C.; Caldwell, J. W.; Ross, W. S.; Kollman, P. A. *Amber 8*; University of California: San Francisco, CA, 2004.
- (28) Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T. *J. Comput. Chem.* **2003**, *24*, 1999.
- (29) (a) Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. *J. Comput. Chem.* **2004**, *25*, 1157. (b) Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. *J. Comput. Chem.* **2005**, *26*, 114.
- (30) Ode, H.; Matsuyama, S.; Hata, M.; Hoshino, T.; Kakizawa, J.; Sugiura, W. *J. Med. Chem.* **2007**, *50*, 1768.
- (31) Cieplak, P.; Cornell, W. D.; Bayly, C.; Kollman, P. A. *J. Comput. Chem.* **1995**, *16*, 1357.
- (32) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; AlLaham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. *Gaussian 03*; Gaussian, Inc.: Wallingford, CT, 2004.
- (33) Ratner, L.; Haseltine, W.; Patarca, R.; Livak, K. J.; Starcich, B.; Josephs, S. F.; Doran, E. R.; Rafalski, J. A.; Whitehorn, E. A.; Baumeister, K.; Ivanoff, L.; Petteway, S. R., Jr.; Pearson, M. L.; Lautenberger, J. A.; Papas, T. S.; Ghuraybparallel, J.; Changparallel, N. T.; Gallo, R. C.; Wong-Staal, F. *Nature* **1985**, *313*, 277.
- (34) Kaldor, S. W.; Kalish, V. J.; Davies, J. F.; Shetty, B. V.; Fritz, J. E.; Appelt, K.; Burgess, J. A.; Campanale, K. M.; Chirgadze, N. Y.; Clawson, D. K.; Dressman, B. A.; Hatch, S. D.; Khalil, D. A.; Kosa, M. B.; Lubbehusen, P. P.; Muesing, M. A.; Patrick, A. K.; Reich, S. H.; Su, K. S.; Tatlock, J. H. *J. Med. Chem.* **1997**, *40*, 3979.
- (35) Krohn, A.; Redshaw, S.; Ritchie, J. C.; Graves, B. J.; Hatada, M. H. *J. Med. Chem.* **1991**, *34*, 3340.
- (36) Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. *J. Chem. Phys.* **1983**, *79*, 926.
- (37) Ryckaert, J.-P.; Ciccoliti, G.; Berendsen, H. J. C. *J. Comput. Phys.* **1977**, *23*, 327.
- (38) Zoete, V.; Michielin, O.; Karplus, M. *J. Mol. Biol.* **2002**, *315*, 21.
- (39) Roberts, N. A.; Martin, J. A.; Kinchington, D.; Broadhurst, A. V.; Craig, J. C.; Duncan, I. B.; Galpin, S. A.; Handa, B. K.; Kay, J.; Krohn, A.; Lambert, R. W.; Merrett, J. H.; Mills, J. S.; Parkes, K. E. B.; Redshaw, S.; Ritchie, A. J.; Taylor, D. L.; Thomas, G. L.; Machin, P. *J. Science* **1990**, *248*, 358.
- (40) Okimoto, N.; Tsukui, T.; Hata, M.; Hoshino, T.; Tsuda, M. *J. Am. Chem. Soc.* **1999**, *121*, 7349.
- (41) Wang, W.; Kollman, P. A. *J. Mol. Biol.* **2000**, *303*, 567.
- (42) Srinivasan, J.; Cheatham, T. E., III; Kollman, P.; Case, D. A. *J. Am. Chem. Soc.* **1998**, *120*, 9401.
- (43) Kollman, P. A.; Massova, I.; Reyes, C.; Kuhn, B.; Huo, S.; Chong, L.; Lee, M.; Lee, T.; Duan, Y.; Wang, W.; Donini, O.; Cieplak, P.; Srinivasan, J.; Case, D. A.; Cheatham, T. E., III *Acc. Chem. Res.* **2000**, *33*, 889.
- (44) Kollman, P. *Chem. Rev.* **1993**, *93*, 2395.
- (45) Onufriev, A.; Bashford, D.; Case, D. A. *Proteins: Struct., Funct., Bioinf.* **2004**, *55*, 383.
- (46) Hoel, P. G. In *Introduction to Mathematical Statistics*, 5th ed.; John Wiley & Sons: New York, 1984; pp 151–160.
- (47) Prabu-Jeyabalan, M.; Nalivaika, E. A.; King, N. M.; Schiffer, C. A. *J. Virol.* **2003**, *77*, 1306.
- (48) Prabu-Jeyabalan, M.; Nalivaika, E. A.; King, N. M.; Schiffer, C. A. *J. Virol.* **2004**, *78*, 12446.

- (49) Tie, Y.; Boross, P. I.; Wang, Y. F.; Gaddis, L.; Liu, F.; Chen, X.; Tozser, J.; Harrison, R. W.; Weber, I. T. *FEBS J.* **2005**, *272*, 5265.
- (50) Sugiura, W.; Matsuda, Zene.; Yokomaku, Y.; Hertogs, K.; Larder, B.; Oishi, T.; Okano, A.; Shiino, T.; Tatsumi, M.; Matsuda, M.; Abumi, H.; Takata, N.; Shirahata, S.; Yamada, K.; Yoshikura, H.; Nagai, Y. *Antimicrob. Agents Chemother.* **2002**, *46*, 708.
- (51) Ode, H.; Ota, M.; Neya, S.; Hata, M.; Sugiura, W.; Hoshino, T. *J. Phys. Chem. B.* **2005**, *109*, 565.
- (52) Ode, H.; Matsuyama, S.; Hata, M.; Neya, S.; Kakizawa, J.; Sugiura, W.; Hoshino, T. *J. Mol. Biol.* **2007**, *370*, 598.
- (53) Ishima, R.; Ghirlando, R.; Tözsér, J.; Gronenborn, A. M.; Torchia, D. A.; Louis, J. M. *J. Biol. Chem.* **2001**, *276*, 49110.
- (54) Louis, J. M.; Ishima, R.; Nesheiwat, I.; Pannell, L. K.; Lynch, S. M.; Torchia, D. A.; Gronenborn, A. M. *J. Biol. Chem.* **2003**, *278*, 6085.
- (55) Coman, R. M.; Robbins, A. H.; Goodenow, M. M.; McKenna, R.; Dunn, B. M. *Acta Crystallogr.* **2007**, *F63*, 320.
- (56) Coman, R. M.; Robbins, A. H.; Goodenow, M. M.; Dunn, B. M.; McKenna, R. *Acta Crystallogr.* **2008**, *D64*, 754.

JP908314F

厚生労働科学研究費補助金エイズ対策研究事業

「HIV感染症の医療体制の整備に関する研究」班
平成22年度 総括・分担研究報告書

発行日 2011年3月31日

発行者 研究代表者 山本 政弘

発行所 研究班事務局
(独) 国立病院機構九州医療センター
AIDS/HIV 総合治療センター
〒810-8563 福岡市中央区地行浜1-8-1

